Jelena Milosevic

Years Active: 2021-2023
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Amy N Sexauer, Gabriela Alexe, Karin Gustafsson, Elizabeth Zanetakos, Jelena Milosevic, Mary L Ayres, Varsha Gandhi, Yana Pikman, Kimberly Stegmaier, David Brian Sykes
DHODH: A promising target in the treatment of T-Acute Lymphoblastic Leukemia. Blood advances (2023)
Jihee Sohn, Jelena Milosevic, Thomas Brouse, Najihah Aziz, Jenna Elkhoury, Suya Wang, Alexander Hauschild, Nick van Gastel, Murat Cetinbas, Sara F Tufa, Douglas R Keene, Ruslan I Sadreyev, William T Pu, David Brian Sykes
A new murine model of Barth syndrome neutropenia links TAFAZZIN deficiency to increased ER stress-induced apoptosis. Blood advances 6 (8) (2022)
Jelena Milosevic, Susanne Fransson, Miklos Gulyas, Thale K Olsen, Gabriel Gallo-Oller, Diana Treis, Lotta H M Elfman, Margareta Wilhelm, Tommy Martinsson, Ninib Baryawno, Per Kogner, John Inge Johnsen
High Expression of PPM1D Induces Tumors Phenotypically Similar to TP53 Loss-of-Function Mutations in Mice. Cancers 13 (21) (2021)
Jelena Milosevic, Diana Treis, Susanne Fransson, Gabriel Gallo-Oller, Baldur Sveinbjörnsson, Nina Eissler, Keiji Tanino, Kazuyasu Sakaguchi, Tommy Martinsson, Malin Wickström, Per Kogner, John Inge Johnsen
PPM1D Is a Therapeutic Target in Childhood Neural Tumors. Cancers 13 (23) (2021)

Jelena Milosevic.css-eqlu8i{font-size:small;padding-left:4px;}